Used in the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin. It is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) on the surface of cancer cells, binding to the receptor's extracellular domain to block ligand binding and inhibit downstream signaling pathways that promote tumor growth, proliferation, and survival. This targeted mechanism helps reduce tumor size, slow disease progression, and improve survival outcomes in eligible patients. Administered intravenously, it is part of precision oncology regimens designed to enhance treatment specificity and minimize damage to healthy tissues compared to traditional chemotherapy.